Meeting
2015 ASCO Annual Meeting
The effect of ipilimumab on natural killer cells identifies the subset of advanced melanoma patients with clinical response.
Authors
Ines Esteves Domingues Pires Da Silva
New York Univ Langone Medcl Ctr, New York, NY
Ines Esteves Domingues Pires Da Silva , Anne Gallois , Kevin P. Lui , Richard L. Shapiro , Anna C. Pavlick , Nina Bhardwaj , Iman Osman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9065)
DOI
10.1200/jco.2015.33.15_suppl.9065
Abstract #
9065
Poster Bd #
308
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2024 ASCO Annual Meeting
Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager.
First Author: Olivier Demaria
Poster
2015 ASCO Annual Meeting
Analysis of CTLA4 expression on T regulatory cells in patients with advanced stage melanoma in the setting of high dose IL-2 (HDIL-2).
First Author: Maggie L. Diller
Poster
2014 ASCO Annual Meeting
Association of natural killer (NK) cell exhaustion with melanoma progression.
First Author: Ines Esteves Domingues Pires Da Silva